

INDEPENDENT ASSESSMENT OF KALA-AZAR ELIMINATION PROGRAMME INDIA

9-20 December 2019, India





INDEPENDENT ASSESSMENT OF KALA-AZAR ELIMINATION PROGRAMME INDIA

9-20 December 2019, India

Title: INDEPENDENT ASSESSMENT OF KALA-AZAR ELIMINATION PROGRAMME INDIA

ISBN: 978-92-9022-796-0

© World Health Organization [2020]

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.

Suggested citation. [Title]. [New Delhi]: World Health Organization, Regional Office for South-East Asia; [2020]. Licence: CC BY-NC-SA 3.0 IGO.

Cataloguing-in-Publication (CIP) data. CIP data are available at <http://apps.who.int/iris>.

Sales, rights and licensing. To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.


This publication on independent assessment of kala-azar does not necessarily represent the decisions or policies of WHO.

Printed in [English]



TABLE OF CONTENTS

Acknowledgements	i
List of abbreviations	ii
Executive summary	1
1. Introduction	8
2. Situational analysis	11
3. General and specific objectives	17
4. Methodology	18
A. Thematic areas	18
B. Selection of team members and team formation	18
C. Selection of field areas for assessment activity	18
D. Data collection at levels and methods	20
5. Observations and recommendations	21
A. Surveillance and organization of preventive and curative services	21
i. Availability of guidelines, use of SoPs, standard uniform terminology and definitions in the programme	21
ii. Case search activity	23
iii. Strengthen the information system to improve data collection, reporting and data use for action plans.	26
iv. Prevention of reestablishment of foci and emergence of new foci environmental management.	28
v. Outbreaks	29
vi. Diagnosis, case management, comorbidities, treatment and adverse drug reactions	32
a. Time elapsed between onset of sign and symptoms and treatment	32
b. Diagnosis and treatment	34
c. Relapses	36
d. Kala-azar and pregnancy	37
e. Post Kala-azar Dermal Leishmaniasis (PKDL)	38
f. HIV-VL co-infection	39



g. Follow-up	40
h. Deaths	40
i. Pharmacovigilance	41
j. Research areas	43
B. Vector control	44
i. General overview	44
ii. Organization of indoor residual spraying (Procedures)	44
iii. Entomological surveillance	51
C. Patient and community participation	54
i. Health-seeking behaviour	54
ii. Community awareness and participation	55
D. Stewardship and governance role of NVBDCP	57
i. Human resources	58
ii. Planning	59
iii. Programme management	60
iv. Award scheme	62
v. Sustaining elimination	62
vi. Collaboration with partners	64
vii. Transborder collaboration	66
E. Budgeting and finance	67
F. Supply chain and stock management	68
G. Best practices	72
H. Operational research	72
6. Limitations of the mission	73
7. Conclusion	74
Annexures	75
Annex 1: Members of the independent assessment mission	75
Annex 2. Recommendations made in 2014 by the independent kala-azar mission and progress made until 2019	76
Annex 3. Terms of reference (ToR) for national task force for neglected tropical diseases	81
Annex 4. Research conducted by stakeholders and official institutions with implications in the Kala-azar elimination programme in India	82





ACKNOWLEDGEMENTS

The independent assessment of the kala-azar (KA) elimination programme accomplished its mission with close assistance and full collaboration of the central directorate of the National Vector Borne Disease Control Programme (NVBDCP), Ministry of Health & Family Welfare, Government of India (MoHFW, GoI) under the overall coordination of the WHO India Country Office (WCO).

The mission members are grateful to the Directorate of Health Services (DHS) at the state level and staff of the State and District Vector Borne Disease Control Programme (DVBDP) in each of the states they visited. It was only because of their support and close coordination of facilitators, that team members were able to visit primary, secondary and tertiary health facilities (public and private), voluntary organizations, community members, households and all those affected by KA and post kala-azar dermal leishmaniasis (PKDL).

The mission benefited immensely from the insight of the senior health administrators, including NVBDCP staff at the national, state and district level, in addition to the key stakeholders at the state, district, primary health centre and sub-centre level. The team would like to thank community-based health worker volunteers, families and individuals whose experiences have contributed to enriching this report.

A special thanks is due to the institutes and individuals who supported in developing the background desk review papers which added tremendous value to the mission's work. These include the Vector Control Research Center (VCRC), Puducherry, the Public Health Foundation of India (PHFI), Dr Rajan Patil, Sri Ram Chandra Medical college, Chennai, Tamil Nadu and Mr Anshuman Bardhan from Chhattisgarh.

WHO Country Office for India wishes to gratefully acknowledge inputs shared by all members (listed in Annex), who dedicated their time and energy to visit the field, collate data and provided recommendations for strengthening the programme implementation.

The mission is thankful to Dr Jorge Alvar for chairing the entire mission along with Co-chair Dr Subhash Salunke, Dr Dhruv K Pandey, respective team leads and rapporteurs. Lastly, a word of thanks to the team of report writers comprising Dr Jorge Alvar, Dr Dhruv K Pandey, Dr Saurabh Jain, Dr Margriet den Boer and Dr Subhash Salunke.

All precautions have been taken to acknowledge contributions and references. However, contributors or WHO will not be responsible for any inadvertent omissions.

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_23411

